SAU · 4016.SR · SAR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 12:14 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SAR. Historical prices are not a forecast.
Middle East Pharmaceutical Industries Company’s quoted price sits in the lower half of its reported 52-week range, 22.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Middle East Pharmaceutical Industries Company’s forward annual dividend is SAR 1.60 per share, paid semi-annual. The forward yield is 2.61% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Middle East Pharmaceutical Industries Company’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of SAR 0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Middle East Pharmaceutical Industries Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Middle East Pharmaceutical Industries Company (MEPIC), established in Riyadh, Saudi Arabia, in 1998, is a global pharmaceutical entity. The company's core activities encompass the entire lifecycle of generic medicines and various pharmaceutical products, from research and development to manufacturing and sales, catering to both local and international markets. Its business operations are strategically divided into private sector, public sector, and export divisions. MEPIC offers an extensive array of products designed to address a wide range of medical conditions. This includes dermatological treatments, remedies for respiratory ailments, central nervous system disorders, digestive issues, and musculoskeletal complaints, alongside medications for the urinary and reproductive systems. Furthermore, the company provides disinfectants and a diverse portfolio of therapeutic agents covering areas such as sexual health, diabetes, cardiovascular diseases, anti-infectives, anti-parasitics, pain relief, antiseptics, and general men's and women's health. These pharmaceutical and health products are supplied in numerous formats, including creams, ointments, syrups, capsules, tablets, gels, lotions, sprays, topical solutions, and personal hygiene items like hand sanitizers, mouthwashes, and soaps. In addition to its proprietary product lines, MEPIC leverages its manufacturing capabilities to offer contract manufacturing services. The company also specializes in cosmetic products, general health aids, and nutritional supplements. Originally known as Middle East Chemical Products Factory Company, the organization officially rebranded to Middle East Pharmaceutical Industries Company in January 2006.
Latest available per-share figures in SAR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 01:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| May 12, 2025 |
| SAR 0.55 |
| SAR 97.00M+1.57% vs estimate |
| Q4 2024 | Feb 18, 2025 | SAR 1.28 | SAR 136.00M-5.88% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | SAR 0.11 | SAR 81.00M-2.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SAR 221.50-SAR 1.60 (-0.72%)
Dr. Sulaiman Al Habib Medical Services Group Company’s quoted price sits in the lower half of its reported 52-week range, 18.57% below the high.
SAR 91.20+SAR 0.20 (+0.22%)
Nahdi Medical Company’s quoted price sits in the lower half of its reported 52-week range, 21.92% below the high.
SAR 55.20-SAR 0.40 (-0.72%)
Mouwasat Medical Services Company’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
SAR 119.90-SAR 2.10 (-1.72%)
Jamjoom Pharmaceuticals Factory Company’s quoted price sits in the lower half of its reported 52-week range, 26.76% below the high.
SAR 6.08-SAR 0.11 (-1.78%)
Saudi Chemical Holding Company’s quoted price sits in the lower half of its reported 52-week range, 32.29% below the high.
SAR 27.42-SAR 0.18 (-0.65%)
Saudi Pharmaceutical Industries and Medical Appliances Corporation’s quoted price sits in the lower half of its reported 52-week range, 17.71% below the high.
SAR 29.80-SAR 2.20 (-6.88%)
Qomel Company Limited’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
SAR 20.99SAR 0.00 (0.0%)
Almujtama Alraida Medical Co.’s quoted price sits in the lower half of its reported 52-week range, 33.37% below the high.
